Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 201–300 of 1,002

Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8 + T‐cell infiltration in the tumor
Singer, K., Kastenberger, M., Gottfried, E., Hammerschmied, C. G., Büttner, M., Aigner, M., Seliger, B., Walter, B., Schlößer, H., Hartmann, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25543 · Cited by 167
VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
Cowey, C. L., & Rathmell, W. K. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0015-5 · Cited by 163
Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents
Ladoire, S., Bonnetain, F., Gauthier, M., Zanetta, S., Petit, J., Guiu, S., Kermarrec, I., Mourey, E., Michel, F., Krause, D., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0227 · Cited by 162
State of the Science: An Update on Renal Cell Carcinoma
Jonasch, E. W., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 165
Renal cell carcinoma: a review of biology and pathophysiology
Nabi, S., Kessler, E. R., Bernard, B. D., Flaig, T. W., & Lam, E. T. (2018) · F1000Research · doi:10.12688/f1000research.13179.1 · Cited by 164
Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
Mack, F. A., Rathmell, W. K., Arsham, A. M., Gnarra, J., Keith, B., & Simon, M. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00240-4 · Cited by 160
Self-citation
Genetic predisposition to kidney cancer
Schmidt, L. S., & Linehan, W. M. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.09.001 · Cited by 163
Self-citation
Epigenetics in renal cell cancer: mechanisms and clinical applications
Joosten, S. C., Smits, K. M., Aarts, M. J. B., Melotte, V., Koch, A., Tjan‐Heijnen, V. C. G., & van Engeland, M. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0023-z · Cited by 166
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression
Schödel, J., Bardella, C., Sciesielski, L. K., Brown, J. M., Pugh, C. W., Buckle, V. J., Tomlinson, I. P. M., Ratcliffe, P. J., & Mole, D. R. (2012) · Nature Genetics · doi:10.1038/ng.2204 · Cited by 163
Overexpression of KIT in chromophobe renal cell carcinoma
Yamazaki, K., Sakamoto, M., Ohta, T., Kanai, Y., Ohki, M., & Hirohashi, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206153 · Cited by 157
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
Jilaveanu, L. B., Shuch, B. M., Zito, C. R., Parisi, F., Barr, M. L., Kluger, Y., Chen, L., & Kluger, H. M. (2014) · Journal of Cancer · doi:10.7150/jca.8167 · Cited by 156
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families.
Kiuru, M. H., Lehtonen, R., Arola, J. T., Salovaara, R., Järvinen, H., Aittomäki, K., Sjöberg, J., Visakorpi, T., Knuutila, S., Isola, J. J., et al. (2002) · PubMed · Cited by 156
Ubiquitination of a Novel Deubiquitinating Enzyme Requires Direct Binding to von Hippel-Lindau Tumor Suppressor Protein
Li, Z., Na, X., Wang, D., Schoen, S. R., Messing, E. M., & Wu, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108269200 · Cited by 155
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
van Kuijk, S. J. A., Yaromina, A., Houben, R. M. A., Niemans, R., Lambin, P., & Dubois, L. J. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00069 · Cited by 157
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.
Duan, D. R., Humphrey, J. S., Chen, D. Y., Weng, Y., Sukegawa, J., Lee, S., Gnarra, J. R., Linehan, W. M., & Klausner, R. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6459 · Cited by 154
Self-citation
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
Lee, S., Chen, D. Y., Humphrey, J. S., Gnarra, J. R., Linehan, W. M., & Klausner, R. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1770 · Cited by 154
Self-citation
Cancer and Leukemia Group B 90206
Rini, B. I., Halabi, S., Taylor, J., Small, E. J., Schilsky, R. L., & for the Cancer Leukemia Group B (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0605 · Cited by 153
Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
Sablin, M., Négrier, S., Ravaud, A., Oudard, S. M., Balleyguier, C., Gautier, J., Celier, C., Médioni, J., & Escudier, B. J. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.02.119 · Cited by 152
N6‐methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO ‐ PGC ‐1α signalling axis
Zhuang, C., Zhuang, C., Luo, X., Huang, X., Lv, Y., Li, J., Li, Y., Xiong, T., Ye, J., Zhang, F., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14128 · Cited by 156
The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy
Sourbier, C., Lindner, V., Lang, H., Agouni, A., Schordan, E., Danilin, S., Rothhut, S., Didier Jacqmin, D., Helwig, J., & Massfelder, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1469 · Cited by 152
Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
Ryan, C. W., Goldman, B. H., Lara, P. N., Mack, P. C., Beer, T. M., Tangen, C. M., Lemmon, D., Pan, C.-X., Drabkin, H. A., & Crawford, E. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.1047 · Cited by 151
The VHL tumor suppressor and HIF: insights from genetic studies in mice
Kapitsinou, P. P., & Haase, V. H. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402313 · Cited by 151
Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics
Linehan, W. M., Pinto, P. A., Srinivasan, R., Merino, M. J., Choyke, P. L., Choyke, L. T., Coleman, J., Toro, J. R., Glenn, G. M., Vocke, C. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1870 · Cited by 151
Self-citation
Genotype-phenotype correlation in von Hippel-Lindau syndrome
Friedrich, C. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.763 · Cited by 149
Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis
Wang, S., Gu, Y., Wolff, N. C., Stefanius, K., Christie, A. L., Dey, A., Hammer, R. E., Xie, X.-J., Rakheja, D., Pedrosa, I., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414789111 · Cited by 152
Mitotic spindle misorientation in cancer – out of alignment and into the fire
Pease, J. C., & Tirnauer, J. S. (2011) · Journal of Cell Science · doi:10.1242/jcs.081406 · Cited by 157
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease
Zatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R., Wiesener, M. S., Eckardt, K., Houlston, R. S., Richards, F. M., Latif, F., & Maher, E. R. (2002) · PubMed · doi:10.25405/ncl.34582002 · Cited by 147
Self-citation
Characterization of the Renal Pathology of a Familial Form of Renal Cell Carcinoma Associated With Von Hippel-Lindau Disease: Clinical and Molecular Genetic Implications
Poston, C. D., Jaffe, G. S., Lubensky, I. A., Solomon, D., Zbar, B., Linehan, W. M., & Walther, M. M. (1995) · The Journal of Urology · doi:10.1097/00005392-199501000-00009 · Cited by 147
Self-citation
VHL Gene Deletion and Enhanced VEGF Gene Expression Detected in the Stromal Cells of Retinal Angioma
Chan, C. C. (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.5.625 · Cited by 146
Review: Cellular Substrates of the Eukaryotic Chaperonin TRiC/CCT
Dunn, A. Y., Melville, M. W., & Frydman, J. (2001) · Journal of Structural Biology · doi:10.1006/jsbi.2001.4380 · Cited by 143
Software and database for the analysis of mutations in the VHL gene
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.256 · Cited by 143
Inactivation of BHD in sporadic renal tumors.
Khoo, S. K., Kahnoski, K., Sugimura, J., Petillo, D., Chen, J., Shockley, K., Ludlow, J. W., Knapp, R., Giraud, S., Richard, S., et al. (2003) · PubMed · Cited by 142
Insertion of Alu element responsible for acute intermittent porphyria
Mustajoki, S., Ahola, H., Mustajoki, P., & Kauppinen, R. (1999) · Human Mutation · doi:10.1002/(sici)1098-1004(1999)13:6 · Cited by 38
von Hippel-Lindau Disease
Couch, V., Lindor, N. M., Karnes, P. S., & Michels, V. V. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.3.265 · Cited by 143
Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein
Lee, S., Neumann, M., Stearman, R. S., Stauber, R. H., Pause, A., Pavlakis, G. N., & Klausner, R. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1486 · Cited by 142
Chemistry of DNA minor groove binding agents
Khan, G. S., Shah, A., Rehman, Z., & Barker, D. L. A. (2012) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2012.07.003 · Cited by 143
Degrons in cancer
Mészáros, B., Kumar, M., Gibson, T. J., Uyar, B., & Dosztányi, Z. (2017) · Science Signaling · doi:10.1126/scisignal.aak9982 · Cited by 147
The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1α in renal cell carcinoma
Clifford, S. C., Astuti, D., Hooper, L., Maxwell, P. H., Ratcliffe, P. J., & Maher, E. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204602 · Cited by 139
Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes
Malouf, G. G., Su, X., Yao, H., Gao, J., Xiong, L., He, Q., Compérat, É., Couturier, J., Molinié, V., Escudier, B. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3036 · Cited by 138
c-Met as a Target for Personalized Therapy
Garajová, I., Giovannetti, E., Biasco, G., & Peters, G. J. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30534 · Cited by 141
Molecular Classification of Renal Tumors by Gene Expression Profiling
Schuetz, A. N., Yin-Goen, Q., Amin, M. B., Moreno, C. S., Cohen, C., Hornsby, C. D., Yang, W., Petros, J. A., Issa, M. M., Pattaras, J. G., et al. (2005) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60547-8 · Cited by 137
A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications.
Chung, D. C., Smith, A. P., Louis, D. N., Graeme‐Cook, F., Warshaw, A. L., & Arnold, A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119547 · Cited by 137
Inactivation of the Arylhydrocarbon Receptor Nuclear Translocator (Arnt) Suppresses von Hippel-Lindau Disease-Associated Vascular Tumors in Mice
Rankin, E. B., Higgins, D. F., Walisser, J. A., Johnson, R. S., Bradfield, C. A., & Haase, V. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3163-3172.2005 · Cited by 140
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy
Clark, P. E. (2009) · Kidney International · doi:10.1038/ki.2009.296 · Cited by 136
Trichloroethylene Exposure and Specific Somatic Mutations in Patients With Renal Cell Carcinoma
Brauch, H. B. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.10.854 · Cited by 137
Self-citation
Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity
Blankenship, C., Naglich, J. G., Whaley, J. M., Seizinger, B. R., & Kley, N. (1999) · Oncogene · doi:10.1038/sj.onc.1202473 · Cited by 136
The von Hippel-Lindau gene, kidney cancer, and oxygen sensing.
Kaelin, W. G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092803.69761.41 · Cited by 135
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma
Gossage, L., Murtaza, M., Slatter, A. F., Lichtenstein, C. P., Warren, A. Y., Haynes, B., Marass, F., Roberts, I., Shanahan, S. J., Claas, A., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22116 · Cited by 137
miR-210: Fine-Tuning the Hypoxic Response
Ivan, M., & Huang, X. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_10 · Cited by 137
HIF-1
Maxwell, P. H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092792.97122.e0 · Cited by 134
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Zhao, B., Zhao, S., SAID, J. W., Merino, M. J., Adeniran, A., Xie, Z., Nawaf, C., Choi, J., Belldegrun, A. S., Pantuck, A. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525735113 · Cited by 134
Genetics and epigenetics of renal cell cancer
Baldewijns, M. M. L. L., van Vlodrop, I. J. H., Schouten, L. J., Soetekouw, P. M. M. B., de Bruı̈ne, A. P., & van Engeland, M. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.12.002 · Cited by 133
PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma
Brugarolas, J. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e3182a102d1 · Cited by 133
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
McKay, R. R., Bossé, D., Xie, W., Wankowicz, S. A. M., Flaifel, A., Moreira, R. B., Lalani, A. A., Martini, D. J., Wei, X. X., Braun, D. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0475 · Cited by 130
Kidney cancer: Identification of novel targets for therapy
Weiss, R. H., & Lin, P.-Y. (2006) · Kidney International · doi:10.1038/sj.ki.5000065 · Cited by 130
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma
Gnarra, J. R., Duan, D. R., Weng, Y., Humphrey, J. S., Chen, D. Y. T., Lee, S. B., Pause, A., Dudley, C. F., Latif, F., Kuzmin, I., et al. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00012-5 · Cited by 130
Self-citation
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
Zurita, A. J., Jonasch, E. W., Wang, X., Khajavi, M., Yan, S., Du, D. Z., Xu, L., Herynk, M. H., McKee, K. S., Tran, H. T., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr047 · Cited by 127
Focus on kidney cancer
Linehan, W. M., & Zbar, B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.006 · Cited by 128
Self-citation
Functionally Impaired TR Mutants Are Present in Thyroid Papillary Cancer
Puzianowska‐Kuźnicka, M., Krystyniak, A., Madej, A., Cheng, S.-Y., & Nauman, J. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8296 · Cited by 127
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Bindra, R. S., Vasselli, J. R., Stearman, R. S., Linehan, W. M., & Klausner, R. D. (2002) · PubMed · Cited by 127
Self-citation
A clear picture of renal cell carcinoma
Hakimi, A. A., Pham, C. G., & Hsieh, J. J.-D. (2013) · Nature Genetics · doi:10.1038/ng.2708 · Cited by 135
Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma
Nosov, D., Esteves, B., Lipatov, O. N., Lyulko, A. A., Anischenko, A. A., Chacko, R. T., Doval, D., Strahs, A. L., Slichenmyer, W. J., & Bhargava, P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.3524 · Cited by 126
The epigenetic landscape of renal cancer
Morris, M. R., & Latif, F. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.168 · Cited by 129
Self-citation
Coexpression of Erythropoietin and Vascular Endothelial Growth Factor in Nervous System Tumors Associated With von Hippel-Lindau Tumor Suppressor Gene Loss of Function
Krieg, M., Marti, H. H., & Plate, K. H. (1998) · Blood · doi:10.1182/blood.v92.9.3388 · Cited by 126
Von Hippel-Lindau disease
Richard, S., Graff, J., Lindau, J., & Resche, F. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15957-6 · Cited by 127
An overview of renal cell cancer: Pathology and genetics
Moch, H. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.006 · Cited by 128
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways.
Jiang, Y., Zhang, W., Kondo, K., Klco, J. M., Martin, T. B. S., Dufault, M. R., Madden, S. F., Kaelin, W. G., & Nacht, M. (2003) · PubMed · Cited by 125
Evaluation of the Clonal Relationship between Primary and Metastatic Renal Cell Carcinoma by Comparative Genomic Hybridization
Bissig, H., Richter, J., Desper, R., Meier, V. S., Schraml, P., Schäffer, A. A., Sauter, G., Mihatsch, M. J., & Moch, H. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65120-6 · Cited by 123
Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma
Morris, M. R., Gentle, D., Abdulrahman, M., Maina, E. N., Gupta, K., Banks, R. E., Wiesener, M. S., Kishida, T., Yao, M., Teh, B. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3371 · Cited by 123
Self-citation
Malignant Renal Tumors
Campbell, S. C., & Lane, B. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00049-9 · Cited by 122
von Hippel-Lindau Tumor Suppressor Protein and Hypoxia-Inducible Factor in Kidney Cancer
Maynard, M. A., & Ohh, M. (2003) · American Journal of Nephrology · doi:10.1159/000075346 · Cited by 126
Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms
Liang Cheng, C., Zhang, S., MacLennan, G. T., Antonio Lopez-beltran, B., & Montironi, R. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.09.009 · Cited by 124
Cell cycle progression in response to oxygen levels
Ortmann, B. M., Druker, J., & Rocha, S. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1645-9 · Cited by 131
Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues
Corless, C. L., Kibel, A. S., Iliopoulos, O., & Kaelin, W. G. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90035-6 · Cited by 121
Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel–Lindau tumor suppressor
Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., & Wu, G. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00534-x · Cited by 119
Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma
Cook, J., Krishnan, S., Karumanchi, S. A., Sells, S. F., Shi, Y., Walther, M. M., Linehan, W. M., Sukhatme, V. P., Weinstein, M. H., & Rangnekar, V. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202416 · Cited by 119
Self-citation
Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis.
Bugert, P., & Kovács, G. (1996) · Europe PMC (PubMed Central) · Cited by 119
Association of microRNA‐34a overexpression with proliferation is cell type‐dependent
Dutta, K. K., 田中, 義., Liu, Y., Yamada, T., Akatsuka, S., Hu, Q., Yoshihara, M., Ohara, H., Takehashi, M., Shinohara, T., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00619.x · Cited by 118
MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma
Green, N. H., Galvan, D. L., Badal, S. S., Chang, B. H., LeBleu, V. S., Long, J., Jonasch, E., & Danesh, F. R. (2019) · Oncogene · doi:10.1038/s41388-019-0869-4 · Cited by 119
Distance-Based Reconstruction of Tree Models for Oncogenesis
Desper, R., Jiang, F., Kallioniemi, O., Moch, H., Papadimitriou, C. H., & Schäffer, A. A. (2000) · Journal of Computational Biology · doi:10.1089/10665270050514936 · Cited by 117
Nephrotoxicity of recent anti-cancer agents
Lameire, N. H. (2013) · Clinical Kidney Journal · doi:10.1093/ckj/sft135 · Cited by 116
Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney
Anglesio, M. S., Evdokimova, V. E., Melnyk, N., Zhang, L., Fernandez, C. V., Grundy, P. E., Leach, S. R., Marra, M. A., Brooks-Wilson, A. R., Penninger, J. M., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh215 · Cited by 117
Influence of the RNA-Binding Protein HuR in pVHL-Regulated p53 Expression in Renal Carcinoma Cells
Galbán, S., Martindale, J. L., Mazan-Mamczarz, K., de Silanes, I. L., Fan, J., Wang, W., Decker, J., & Gorospe, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7083-7095.2003 · Cited by 120
HypoxamiRs and Cancer: From Biology to Targeted Therapy
Gee, H. E., Ivan, C., Călin, G. A., & Ivan, M. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5639 · Cited by 119
Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers
Su, C., Lv, Y., Lu, W., Yu, Z., Ye, Y., Guo, B., Liu, D., Yan, H., Li, T., Zhang, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719564 · Cited by 123
Renal Toxicity and Carcinogenicity of Trichloroethylene: Key Results, Mechanisms, and Controversies
Brüning, T., & Bolt, H. M. (2000) · Critical Reviews in Toxicology · doi:10.1080/10408440091159202 · Cited by 115
Tumour specific promoter region methylation of the human homologue of the Drosophila Roundabout gene DUTT1 (ROBO1) in human cancers
Dallol, A., Forgacs, E., Martínez, A., Sekido, Y., Walker, R. A., Kishida, T., Rabbitts, P. H., Maher, E. R., Minna, J. D., & Latif, F. (2002) · Oncogene · doi:10.1038/sj.onc.1205421 · Cited by 114
Self-citation
Renal cell carcinoma
Motzer, R. J., Nanus, D. M., Russo, P., & Berg, W. J. (1997) · Current Problems in Cancer · doi:10.1016/s0147-0272(97)80007-4 · Cited by 113
Tumor Biology and Prognostic Factors in Renal Cell Carcinoma
Finley, D. S., Pantuck, A. J., & Belldegrun, A. S. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s2-04 · Cited by 116
Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene.
Ma, W., Tessarollo, L., Hong, S., Baba, M., Southon, E. A., Back, T. C., Spence, S. E., Lobe, C. G., Sharma, N. D., Maher, G., et al. (2003) · PubMed · Cited by 112
Self-citation
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study
van Houwelingen, K. P., van Dijk, B. A. C., de Kaa, C. A. H., Schouten, L. J., Gorissen, H., Schalken, J. A., van den Brandt, P. A., & Oosterwijk, E. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-57 · Cited by 112
Renal cysts, renal cancer and von Hippel-Lindau disease
Neumann, H. P. H., & Zbar, B. (1997) · Kidney International · doi:10.1038/ki.1997.3 · Cited by 112
Self-citation
Von Hippel–Lindau: How a rare disease illuminates cancer biology
Richard, S., Gardie, B., Couvé, S., & Gad, S. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.05.005 · Cited by 121
Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model
Verheul, H. M. W., Hammers, H. J., van Erp, K., Wei, Y., Sanni, T. B., Salumbides, B. C., Qian, D. Z., Yancopoulos, G. D., & Пили, Р. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2553 · Cited by 111
Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
Uhlman, D. L., Nguyen, P., Manivel, J. C., Zhang, G., Hagen, K., Fraley, E. E., Aeppli, D. M., & Niehans, G. A. (1995) · PubMed · Cited by 111
Nox4 Is Critical for Hypoxia-Inducible Factor 2-α Transcriptional Activity in von Hippel-Lindau–Deficient Renal Cell Carcinoma
Maranchie, J. K., & Zhan, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2105 · Cited by 115
Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe
Glavač, D., Neumann, H. P. H., Wittke, C., Jaenig, H., Masek, O., Streicher, T., Pausch, F., Engelhardt, D., Plate, K. H., Höfler, H., et al. (1996) · Human Genetics · doi:10.1007/s004390050206 · Cited by 110
Self-citation
MUC1, a New Hypoxia Inducible Factor Target Gene, Is an Actor in Clear Renal Cell Carcinoma Tumor Progression
Aubert, S., Fauquette, V., Hémon, B., Lepoivre, R., Briez, N., Bernard, D., SEUNINGEN, I. V., Leroy, X., & Perrais, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4905 · Cited by 121
Hereditary kidney cancer
Linehan, W. M., Pinto, P. A., Bratslavsky, G., Pfaffenroth, E. C., Merino, M. J., Vocke, C. D., Toro, J. R., Bottaro, D. P., Neckers, L., Schmidt, L. S., et al. (2009) · Cancer · doi:10.1002/cncr.24230 · Cited by 112
Self-citation
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Martínez‐Sáez, O., Borau, P. G., Alonso‐Gordoa, T., Molina‐Cerrillo, J., & Grande, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.013 · Cited by 111

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks